Could EMERALD-3 redefine the treatment paradigm for unresectable hepatocellular carcinoma?In this special roundtable discussion recorded at ASCO 2026, Dr. Ghassan Abou-Alfa is joined by Dr. Gentry King, Dr. Mehmet Akce, Dr. Pierre Gholam, Dr. Lingling Du, Dr. Adam Burgoyne, Dr. Lipika Goyal, and Dr. Riad Salem to break down the landmark EMERALD-3 study.The panel explores the scientific rationale for combining transarterial chemoembolization (TACE) with immunotherapy and antiangiogenic therapy, while reviewing key efficacy findings from the EMERALD-3 study. Beyond the data, the experts discuss how locoregional therapies can enhance immune responses, and examine the practical challenges of patient selection, multidisciplinary decision-making, treatment sequencing, and the evolving role of interventional radiology in modern HCC management.Topics discussed include:EMERALD-3 trial design and resultsTACE plus systemic therapy in HCCDurvalumab and immunotherapy strategiesLenvatinib and antiangiogenic therapySynergy between embolization and immunotherapyLocoregional therapy in unresectable HCCProgression-free survival and clinical outcomesMultidisciplinary management of liver cancerInterventional radiology and oncology collaborationPatient selection for combination therapyFuture directions in hepatocellular carcinoma treatmentHow EMERALD-3 may influence clinical practiceAs treatment options continue to expand, understanding how systemic therapy and locoregional interventions work together may be key to improving outcomes for patients with liver cancer.Subscribe for more expert oncology discussions, clinical trial updates, and insights from leading cancer specialists.–Thanks for watching!Our podcasts are also available on:Spotify - https://spotf.fi/chm-podcastAmazon Music - https://amazn.so/chm-podcastApple Podcast - https://podcasts.apple.com/us/podcast...Castbox - https://castbox.fm/vh/6735434Goodpods - https://goodpods.com/profile/chm-111066iHeartRadio - https://iheart.com/podcast/291542082Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in:Peer to peer interviews, panels & round-tablesCurated live events & conferencesProfessional in-depth content & research updatesInteractive learning modules & webinarsLive & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media
続きを読む
一部表示
55 分
32 分
2026/06/2633 分
2026/06/2639 分
1 時間 2 分
1 時間 15 分
53 分